title: Nonallergic Eyelid Edema After Botulinum Toxin Type A Injection: Case Report and Review of Literature.
abstract: Periocular botulinum toxin type A (BoNTA) injections are generally safe. Ptosis is the most common adverse effect, whereas eyelid edema is rarely reported. There is no consensus on the latter's incidence, clinical course, or treatment strategy. Here we managed a 59-year-old woman who received BoNTA injections to her forehead, glabella, and eye corner. At 3-day follow-up, she presented with painless, nonpruritic, bilateral periorbital edema, and erythema. Preliminary diagnosis was a local allergic reaction, and topical corticosteroid was administered, but upon lack of improvement, edema secondary to venous and lymphatic congestion was hypothesized, and she was advised to apply hot pads over her eyes, blink frequently, and massage the area. Her eyelid edema resolved 2 weeks later. At 4-month follow-up, the patient requested and received another course of BoNTA at half the dose. Frequent blinking was instructed, and the patient reported a satisfactory outcome with no adverse effects. In our literature review, incidence of BoNTA-induced eyelid edema was 1.4% and showed Asian tendency. Although rare, BoNTA-induced periorbital edema is self-limiting, and normally resolves in 2 to 4 weeks without medical treatment. Patients at risk for edema, including Asian ethnicity, dermatochalasis, and poor periocular muscle tone, are advised to receive injections at half the dosage. Examination of the function and tone of the orbicularis oculi and levator palpebrae superioris muscles before treatment is recommended, and application of hot pads over the eyes, frequent blinking in the morning, and self-massage of the affected area to increase venous return have demonstrated to improve outcome.
authors.affiliation: From the Department of Dermatology (Y-SC), Taipei Medical University Hospital, Taipei City, Taiwan; Aesthetic Medicine Center (Y-SC, C-CC, J-HS), Department of Plastic Surgery, Chang Gung Memorial Hospital, Puzi City, Chiayi County, Taiwan; Department of Cosmetic Science (C-CC), Chang Gung University of Science and Technology, Kwei-Shan, Taoyuan, Taiwan; Department of Ophthalmology (J-HS), Chang-Gung Memorial Hospital, Taoyuan County, Taiwan; Department of Dermatology (Y-TC), Shung Ho Hospital, New Taipei City, Taiwan; and Hospital Authority (KK-WC), Hong Kong SAR.
authors.forename: Yin-Shuo
authors.initials: YS
authors.lastname: Chang
authors.forename: Chang-Cheng
authors.initials: CC
authors.lastname: Chang
authors.forename: Jen-Hsiang
authors.initials: JH
authors.lastname: Shen
authors.forename: Yu-Tsung
authors.initials: YT
authors.lastname: Chen
authors.forename: Karen Kar-Wun
authors.initials: KK
authors.lastname: Chan
mesh_terms: D019274:Botulinum Toxins, Type A / Q000009:adverse effects*; D004487:Edema / Q000139:chemically induced*; D004890:Erythema / Q000139:chemically induced*; D005141:Eyelid Diseases / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009465:Neuromuscular Agents / Q000009:adverse effects*
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A